Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Abnormal accumulation of β-amyloid (Aβ) in Alzheimer's disease (AD) is associated with prominent brain inflammation. Whereas earlier studies concluded that this inflammation is detrimental, more recent animal data suggest that at least some inflammatory processes may be beneficial and promote Aβ clearance. Consistent with these observations, overproduction of transforming growth factor (TGF)-β1 resulted in a vigorous microglial activation that was accompanied by at least a 50% reduction in Aβ accumulation in human amyloid precursor protein (hAPP) transgenic mice. In a search for inflammatory mediators associated with this reduced pathology, we found that brain levels of C3, the central component of complement and a key inflammatory protein activated in AD, were markedly higher in hAPP/TGF-β1 mice than in hAPP mice. To assess the importance of complement in the pathogenesis of AD-like disease in mice, we inhibited C3 activation by expressing soluble complement receptor-related protein y (sCrry), a complement inhibitor, in the brains of hAPP mice. Aβ deposition was 2- to 3-fold higher in 1-year-old hAPP/sCrry mice than in age-matched hAPP mice and was accompanied by a prominent accumulation of degenerating neurons. These results indicate that complement activation products can protect against Aβ-induced neurotoxicity and may reduce the accumulation or promote the clearance of amyloid and degenerating neurons. These findings provide evidence for a role of complement and innate immune responses in AD-like disease in mice and support the concept that certain inflammatory defense mechanisms in the brain may be beneficial in neurodegenerative disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“other studies have reported that inhibition of different components of complement impaired Aβ phagocytosis, resulting in elevated synapse loss.”
From Microglia in Alzheimer's disease (2017) · cites this paper as [122]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The deficiency of complement factors such as C1q, C3, C3ar1, C5aR, and Cd59, has exacerbated neuropathology in some studies [84–86] and reduced neuropathology in others [87–89].”
From Age, sex and Alzheimer’s disease: a longitudinal study of 3xTg-AD mice reveals sex-specific disease trajectories and inflammatory responses mirrored in postmortem brains from Alzheimer’s patients (2024) · cites this paper as [85]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the same studies, complement blockade was associated with increased neurodegeneration.”
From Microglia in Alzheimer's disease (2017) · cites this paper as [122]
The cited source says what the claim attributes to it.
In the citing paper
“C3 inhibition enhanced plaque deposition and promoted neurodegeneration in J20 hAPP mice either by over-expression of sCrry (22) or genetic deletion of C3 (21).”
From Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice (2017) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“Further, studies manipulating the complement system have yielded mixed results.”
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Self-citationImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Cellular Scaling Rules for the Brains of Marsupials: Not as “Primitive” as Expected
Dos Santos, S. E., Porfirio, J., da Cunha, F. B., Manger, P. R., Tavares, W., Pessoa, L., Raghanti, M. A., Sherwood, C. C., & Herculano-Houzel, S. (2017) · Brain, Behavior and Evolution · doi:10.1159/000452856 · Cited by 2,642
NeuN, a neuronal specific nuclear protein in vertebratesxs
Mullen, R. J., Buck, C. R., & Smith, A. M. (1992) · Development · doi:10.1242/dev.116.1.201 · Cited by 2,351
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856
Self-citationAβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,498
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies
Botto, M., Dell' Agnola, C., Bygrave, A. E., Thompson, E. M., Cook, H. T., Petry, F., Loos, M., Pandolfi, P. P., & Walport, M. J. (1998) · Nature Genetics · doi:10.1038/ng0598-56 · Cited by 1,434
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235
Self-citation
Research works printed but not linked: 4
- Wyss-Coray, T. & Mucke, L. (2002) Neuron, in press. [DOI] [PubMed]
- Terry R. D., Masliah, E. & Hansen, L. A. (1994) in Alzheimer Disease, eds. Terry, R. D., Katzman, R. & Bick, K. L. (Raven, New York), pp. 179–196.
- Frautschy S. A., Cole, G. M. & Baird, A. (1992) Am. J. Pathol. 140, 1389-1399. [PMC free article] [PubMed] [Google Scholar]
- Holers V. M. (1996) in Clinical Immunology: Principles and Practice, ed. Rich, R. R. (Mosby, St. Louis), pp. 363–391.
Cited by
Items 101–200 of 466
Genetic Susceptibility for Alzheimer Disease Neuritic Plaque Pathology
Shulman, J. M., Chen, K., Keenan, B. T., Chibnik, L. B., Fleisher, A., Thiyyagura, P., Roontiva, A., McCabe, C., Patsopoulos, N. A., Corneveaux, J. J., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.2815 · Cited by 160
Chronic Stress Weakens Connectivity in the Prefrontal Cortex: Architectural and Molecular Changes.
Woo, E., Sansing, L. H., Arnsten, A. F. T., & Datta, D. (2021) · Chronic Stress · doi:10.1177/24705470211029254 · Cited by 159
Why Pleiotropic Interventions are Needed for Alzheimer's Disease
Frautschy, S. A., & Cole, G. M. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8137-1 · Cited by 146
“Consistent with this idea, inhibiting C3 activation by expressing soluble complement receptor-related protein Y (sCrry) was shown to exacerbate pathogenesis in the AD model [65].”
BackgroundKoenigsknecht-Talboo, J., Meyer-Luehmann, M., Parsadanian, M., Garcia-Alloza, M., Finn, M. B., Hyman, B. T., Bacskai, B. J., & Holtzman, D. M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4147-08.2008 · Cited by 149
“Inhibition of the complement cascade has been associated with an increase in A pathology and degenerating neurons as well as an alteration in microglial responses (Wyss-Coray et al., 2002; Maier et al., 2008).”
BackgroundXiong, Z.-Q., Qian, W., Suzuki, K., & McNamara, J. O. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-03-00955.2003 · Cited by 145
“, 2002); importantly, the increased A peptide deposition is accompanied by enhanced neurodegeneration in these mice (Wyss-Coray et al., 2002).”
BackgroundMicroglial inflammation and phagocytosis in Alzheimer's disease: Potential therapeutic targets
Nizami, S., Hall‐Roberts, H., Warrier, S., Cowley, S. A., & Di Daniel, E. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14618 · Cited by 147
Bergamaschini, L., Rossi, E., Storini, C., Pizzimenti, S., Distaso, M., Perego, C., De Luigi, A., Vergani, C., & Grazia De Simoni, M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0550-04.2004 · Cited by 146
“There is also evidence of a protective role for complement in AD pathology, because overexpression of the natural inhibitor C3 in APP transgenic mice results in an increase of A deposition and neuronal loss (Wyss-Coray et al., 2002).”
BackgroundBenoit (2011) · doi:10.1523/jneurosci.3932-10.2011 · Cited by 144
“In contrast, other studies have provided evidence for a beneficial role for complement activation products (Wyss-Coray et al., 2002; Rus et al., 2005; Maier et al., 2008), and more recent studies have demonstrated an unexpected role of the early complement cascade C1 through C3 in removing unwanted synapses (i.”
ResultHauwel, M., Furon, E., Canova, C., Griffiths, M., Neal, J. W., & Gasque, P. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.12.012 · Cited by 167
Glial cell dysregulation: a new perspective on Alzheimer disease
Rommy von Bernhardi, M. (2007) · Neurotoxicity Research · doi:10.1007/bf03033906 · Cited by 157
Genetics of Alzheimer's disease: new evidences for an old hypothesis?
Lambert, J., & Amouyel, P. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2011.02.002 · Cited by 172
“This complement pathway may potentially favour clearance of amyloid fibrils and apoptotic cells [41].”
BackgroundComplement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer’s disease
Zhou, J., Fonseca, M. I., Pisalyaput, K., & Tenner, A. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05558.x · Cited by 130
“Interestingly, in another murine model the over-expression of an inhibitor of complement C3, Crry, resulted in increased pathology, suggesting that some complement activation fragments (such as C3b, C3a, or C5a) may decrease the neuropathology in mouse models of inflammation including those over-expressing mutant APP…”
BackgroundInfluentialWalker, L. C. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-3025 · Cited by 174
Sewell, D. L., Nacewicz, B. M., Liu, F., Macvilay, S., Erdei, A., Lambris, J. D., Sándor, M., & Fábry, Z. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.06.003 · Cited by 146
“There is further evidence that the complement system may play an important role in neurodegenerative conditions such as Alzheimer’s disease (AD) (Bergamaschini et al., 1999; Bradt et al., 1998; Cooper et al., 2000; Fischer et al., 1995; Shen et al., 1998; Veerhuis et al., 1995, 1996; Walker and McGeer, 1992; Wyss-Cora…”
BackgroundSelf-citationYamamoto, M., Horiba, M., Buescher, J. L., Huang, D., Gendelman, H. E., Ransohoff, R. M., & Ikezu, T. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62364-4 · Cited by 137
“Furthermore, APP mice overexpressing C3 inhibitor, soluble complement receptor-related protein y, show reduced microglial activities and enhanced A deposition.(16) CCL2 is a member of the chemokine subfamily and a signaling ligand for the seven-transmembrane spanning G-protein-coupled receptor, CCR2.”
BackgroundNeurodegeneration and demyelination in multiple sclerosis
Garton, T. P., Gadani, S. P., Gill, A. J., & Calabresi, P. A. (2024) · Neuron · doi:10.1016/j.neuron.2024.05.025 · Cited by 145
The complement cascade as a therapeutic target in intracerebral hemorrhage
Ducruet, A. F., Zacharia, B. E., Hickman, Z. L., Grobelny, B. T., Yeh, M. L., Sosunov, S. A., & Connolly, E. S. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.018 · Cited by 129
“This has been observed in transgenic models of neurodegeneration in both systemic lupus erythematosus and Alzheimer's disease (Alexander et al., 2005; Wyss-Coray et al., 2002).”
BackgroundGenome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers
Jansen, I. E., van der Lee, S. J., Gomez-Fonseca, D., de Rojas, I., Dalmasso, M. C., Grenier-Boley, B., Zettergren, A., Mishra, A., Ali, M., Andrade, V., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02454-z · Cited by 132
“In addition, genome-wide association studies (GWAS) in AD have convincingly highlighted the importance of microglia [33, 56], a finding previously supported by research from other scientific fields [18, 72, 75], and now also widely accepted as a genetic cause rather than a result of AD pathogenesis.”
BackgroundNeuroprotection in stroke by complement inhibition and immunoglobulin therapy
Arumugam, T. V., Woodruff, T. M., Lathia, J. D., Selvaraj, P. K., Mattson, M. P., & Taylor, S. M. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2008.07.015 · Cited by 125
“…activation could induce cell lysis and cause cell death (Shen et al., 1997; Fonseca et al., 2004); on the other side, complement components such as C1q and C3b can promote the clearance of cellular debris and apoptotic cells and enhance cell survival (Wyss-Coray et al., 2002; Rus et al., 2006).”
BackgroundPiirainen, S., Youssef, A. M., Song, C., Kalueff, A. V., Landreth, G. E., Malm, T., & Tian, L. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.01.046 · Cited by 136
Complement dysregulation in the central nervous system during development and disease
Lee, J. D., Coulthard, L. G., & Woodruff, T. M. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101340 · Cited by 128
Gan, L., Ye, S., Chu, A., Anton, K., Yi, S., Vincent, V. A., von Schack, D., Chin, D., Murray, J., Lohr, S., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306183200 · Cited by 126
The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects
Sleegers, K., Lambert, J.-C., Bertram, L., Cruts, M., Amouyel, P., & Van Broeckhoven, C. (2010) · Trends in Genetics · doi:10.1016/j.tig.2009.12.004 · Cited by 129
Boyd, T. D., Bennett, S. P., Mori, T., Governatori, N., Runfeldt, M., Norden, M., Padmanabhan, J., Neame, P., Wefes, I., Sanchez-Ramos, J., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091471 · Cited by 128
Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease
Schwab, C., Hosokawa, M., & McGeer, P. L. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.03.016 · Cited by 143
Microglial complement receptor 3 regulates brain Aβ levels through secreted proteolytic activity
Czirr, E., Castello, N. A., Mosher, K. I., Castellano, J. M., Hinkson, I. V., Lucin, K. M., Baeza-Raja, B., Ryu, J. K., Li, L., Farina, S. N., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162011 · Cited by 126
“Complement proteins are important for removal of Aβ deposits, and interference with the central component C3 results in increased plaque deposition (Wyss-Coray et al., 2002; Maier et al., 2008).”
BackgroundSelf-citationNeuronal death in Alzheimer’s disease and therapeutic opportunities
Donev, R., Kolev, M., Millet, B., & Thome, J. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00889.x · Cited by 126
“Astrocytes and microglia in the CNS produce both soluble complement regulatory proteins (CReg) and membrane-bound CReg (CD59, CD55, CD46) [72], which ensures a good level of protection against complement lysis by inhibiting MAC formation.”
BackgroundInfluentialPhagocytosis of Amyloid-β and Inflammation: Two Faces of Innate Immunity in Alzheimer's Disease
Fiala, M., Cribbs, D. H., Rosenthal, M., & Bernard, G. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-11406 · Cited by 124
Wilhelmus, M. M. M., de Waal, R. M. W., & Verbeek, M. M. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0029-7 · Cited by 122
Reichwald, J., Danner, S., Wiederhold, K.-H., & Staufenbiel, M. (2009) · Journal of Neuroinflammation · doi:10.1186/1742-2094-6-35 · Cited by 121
“These data are consistent with the increased C3 expression described in the J20 APP transgenic mouse line [27].”
The Genetics of Alzheimer’s Disease
Barber, R. C. (2012) · Scientifica · doi:10.6064/2012/246210 · Cited by 101
Modulation of inflammation in transgenic models of Alzheimer’s disease
Birch, A. M., Katsouri, L., & Sastre, M. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-25 · Cited by 121
“Unlike the increases in Aβ pathology shown in PDAPP J20 [48], suppression of inflammation by overexpressing the complement inhibitory factor sCrry in P301L tau Tg mice resulted in reduced tau pathology [49].”
BackgroundPhagocytic Clearance in Neurodegeneration
Sokolowski, J. D., & Mandell, J. W. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.051 · Cited by 130
“In hAPP transgenic mice, complement C3 deficiency caused by overexpression of a complement inhibitor, soluble complement receptor-related protein y (Scrry), or by knockout, results in increased A plaque deposition.(59,60) This suggests that complement may help prevent plaque formation, perhaps acting as an opsonin for…”
BackgroundC3- and CR3-dependent microglial clearance protects photoreceptors in retinitis pigmentosa
Silverman, S. M., Ma, W., Wang, X., Zhao, L., & Wong, W. T. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20190009 · Cited by 119
The complement cascade in the regulation of neuroinflammation, nociceptive sensitization, and pain
Warwick, C. A., Keyes, A. L., Woodruff, T. M., & Usachev, Y. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101085 · Cited by 124
“Similarly, in murine models of AD, inhibition or genetic knockout of C3 worsens AD pathology, which is characterized by higher levels of Aβ deposition and neuronal death that in complement sufficient animals (84, 85).”
BackgroundNeuro-Immune Hemostasis: Homeostasis and Diseases in the Central Nervous System
De Luca, C., Colangelo, A. M., Alberghina, L., & Papa, M. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00459 · Cited by 118
Stilling, R. M., Benito, E., Barth, J., Gertig, M., Capece, V., Burckhardt, S., Bonn, S., & Fischer, A. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00373 · Cited by 116
“…2003; Fonseca et al., 2004; Leinhase et al., Frontiers in Cellular Neuroscience www.frontiersin.org November 2014 | Volume 8 | Article 373 | 10 2006; Kulkarni et al., 2008, 2011; Pillay et al., 2008), yet this data remains controversial (Wyss-Coray et al., 2002; Loeffler, 2004; Maier et al., 2008).”
BackgroundNogueras-Ortiz, C. J., Mahairaki, V., Delgado-Peraza, F., Das, D., Avgerinos, K., Eren, E., Hentschel, M., Goetzl, E. J., Mattson, M. P., & Kapogiannis, D. (2020) · Cells · doi:10.3390/cells9071618 · Cited by 106
“Furthermore, genome wide association studies (GWAS) associated CR1 (gene encoding the receptor for C3b/4b) with late onset AD [22]; the interaction between C3b and CR1 mediates Aβ phagocytosis [23]; thus, polymorphisms altering the CR1 function could decrease Aβ clearance.”
BackgroundImmunotherapies for Neurodegenerative Diseases
Mortada, I., Farah, R., Nabha, S. M., Ojcius, D. M., Fares, Y., Almawi, W. Y., & Sadier, N. S. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.654739 · Cited by 125
Bohlson, S. S., & Tenner, A. J. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101921-035639 · Cited by 115
Eikelenboom, P., Hoozemans, J. J., Veerhuis, R., van Exel, E., Rozemuller, A. J., & van Gool, W. A. (2012) · Alzheimer's Research & Therapy · doi:10.1186/alzrt118 · Cited by 109
“However, it appeared that complement C3 defi ciency in transgenic AD mice led to accelerated amyloid plaque formation and overexpression of IL-1β to a reduction of amyloid pathology [21,22,80].”
BackgroundImmunity and inflammation in neurodegenerative diseases.
Cappellano, G., Carecchio, M., Fleetwood, T., Magistrelli, L., Cantello, R. M., Dianzani, U., & Comi, C. (2013) · Europe PMC (PubMed Central) · Cited by 143
Systemic and Acquired Immune Responses in Alzheimer's Disease
Britschgi, M., & Wyss‐Coray, T. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(07)82011-3 · Cited by 120
Self-citationBoche, D., & Nicoll, J. A. R. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00134.x · Cited by 104
“In APP transgenic mice which have inhibition of the complement system at the level of C3 (the central component of complement), neurodegeneration is increased compared with non complement-inhibited controls (123).”
Microglial Activation in Alzheimers Disease
Schlachetzki, J., & Hull, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509790147179 · Cited by 104
Complement-Mediated Events in Alzheimer’s Disease: Mechanisms and Potential Therapeutic Targets
Tenner, A. J. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901068 · Cited by 108
“Greater amyloid accumulation and greater cognitive deficits were observed in the C3-deficient or Crry-overexpressing mice (94, 104), suggesting a beneficial role for activated C3.”
BackgroundKeene, C. D., Cudaback, E., Li, X., Montine, K. S., & Montine, T. J. (2011) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2011.08.002 · Cited by 103
Pisalyaput, K., & Tenner, A. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05012.x · Cited by 103
“However, the findings presented here of a neuroprotective function for C1q add a potentially neuroprotective role for this protein, which is consistent with the recent reports of additional functions for complement proteins both in disease as well as development (Wyss-Coray et al. 2002; Mastellos et al. 2005).”
ResultThe coarse-grained plaque: a divergent Aβ plaque-type in early-onset Alzheimer’s disease
Boon, B. D. C., Bulk, M., Jonker, A. J., Morrema, T. H. J., van den Berg, E., Popovic, M., Walter, J., Kumar, S., van der Lee, S. J., Holstege, H., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02198-8 · Cited by 93
Metabolism of amyloid β peptide and pathogenesis of Alzheimer's disease
Saido, T. C., & Iwata, N. (2006) · Neuroscience Research · doi:10.1016/j.neures.2005.12.015 · Cited by 112
From development to dysfunction: Microglia and the complement cascade in CNS homeostasis
Zabel, M. K., & Kirsch, W. M. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.02.001 · Cited by 97
“001 increase in A deposition and prominent neuronal degeneration in hAPP/sCrry mice compared to age-matched hAPP littermates (Wyss-Coray et al., 2002).”
Mechanisms of amyloid plaque pathogenesis
Fiala, J. C. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0284-8 · Cited by 113
Ohmi, Y., Tajima, O., Ohkawa, Y., Mori, A., Sugiura, Y., Furukawa, K., & Furukawa, K. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912336106 · Cited by 110
Dai, C.-L., Hu, W., Tung, Y. C., Liu, F., Gong, C.-X., & Iqbal, K. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0341-7 · Cited by 99
“Knockout of C3 or overexpression of complement receptor-related protein y (Crry), an inhibitor of complement C3 convertase, increases the amyloid load but reduces phagocytic microglia [61, 62].”
BackgroundOhmi, Y., Tajima, O., Ohkawa, Y., Yamauchi, Y., Sugiura, Y., Furukawa, K., & Furukawa, K. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07067.x · Cited by 112
“As novel functions in development (Bénard et al. 2004; Stevens et al. 2007), neurogenesis in adults (Rahpeymai et al. 2006), and protection in disease-susceptible mutant mice like Tg/Ab have been reported (Wyss-Coray et al. 2002).”
BackgroundInflammation in transgenic mouse models of neurodegenerative disorders
Schwab, C., Klegeris, A., & McGeer, P. L. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.013 · Cited by 97
Echeverria, V., Yarkov, A., & Aliev, G. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.002 · Cited by 91
Fonseca, M. I., Chu, S.-H., Berci, A. M., Benoit, M. E., Peters, D. G., Kimura, Y., & Tenner, A. J. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-4 · Cited by 79
“For example, transgenic over expression of the murine complement inhibitor of C3 (Crry) or generation of a C3 deficient APP mice resulted in enhanced pathology in these mouse models suggesting a protective contribution of complement [41,43] (possibly due to the opsonic effect of C3b for amyloid or cellular debris that…”
Moriyama, M., Fukuhara, T., Britschgi, M., He, Y., Narasimhan, R., Villeda, S., Molina, H., Huber, B. T., Holers, M., & Wyss-Coray, T. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3617-10.2011 · Cited by 93
“The complement system is best known for its critical functions in the immune system, but a growing number of studies have tied complement factors genetically to neurodegenerative diseases in humans and mice (Wyss-Coray et al., 2002; Haines et al., 2005; Klein et al., 2005; Maier et al., 2008).”
BackgroundInfluentialSelf-citationThe Inflammatory Response in Alzheimer's Disease
Rogers, J. (2008) · Journal of Periodontology · doi:10.1902/jop.2008.080171 · Cited by 92
Rathore, N., Ramani, S. R., Pantua, H., Payandeh, J., Bhangale, T., Wuster, A., Kapoor, M., Sun, Y., Kapadia, S. B., Gonzalez, L., et al. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007427 · Cited by 93
Mice as models: Transgenic approaches and Alzheimer's disease
Games, D., Buttini, M., Kobayashi, D., Schenk, D., & Seubert, P. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s316 · Cited by 92
“Since C3, a central component of the complement-mediated inflammatory cascade, was elevated in the brains of TGF-β 1/ β APP bigenic mice, Wyss-Coray and his colleagues created another line of bigenic mice to determine the role of C3 in plaque deposition [114].”
Sharma, A., Kazim, S. F., Larson, C. S., Ramakrishnan, A., Gray, J. D., McEwen, B. S., Rosenberg, P. A., Shen, L., & Pereira, A. C. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903566116 · Cited by 92
Sayed, A., Bahbah, E. I., Kamel, S., Barreto, G. E., Ashraf, G. M., & Elfil, M. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577398 · Cited by 97
Yin and Yang: complement activation and regulation in Alzheimer’s disease
Shen, Y., & Meri, S. (2003) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2003.08.001 · Cited by 102
Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases
Dhib-Jalbut, S. S., Arnold, D. L., Cleveland, D. W., Fisher, M., Friedlander, R. M., Mouradian, M. M., Przedborski, S., Trapp, B. D., Wyss‐Coray, T., & Yong, V. W. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.03.027 · Cited by 97
“These mice are largely protected from excitotoxic injury and when crossed with a mouse model for Alzheimer's disease, they develop less amyloid deposition (Wyss-Coray et al., 2002; Buckwalter and Wyss-Coray, 2004).”
BackgroundInfluentialSelf-citationDepboylu, C., Schäfer, M. K.-H., Arias-Carrión, O., Oertel, W. H., Weihe, E., & Höglinger, G. U. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31820805b9 · Cited by 89
“On the other hand, complement activation can inversely reduce neurodegeneration and plaque formation in a mouse model of Alzheimer disease (14) and is critical for the immune response in neuroinfectious diseases (15).”
BackgroundZhu, X., Yu, J., Jiang, T., Wang, P., Cao, L., & Tan, L. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8723-8 · Cited by 94
Microglia, Alzheimer's Disease, and Complement
Crehan, H., Hardy, J., & Pocock, J. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/983640 · Cited by 84
“Human-APP transgenic mice expressing the soluble form of the C3 convertase inhibitor Crry (sCrry), (thus hAPP/sCrry mice), showed a 2- to 3fold higher deposition of Aβ deposits and an accumulation of degenerating neurons compared with the hAPP mice [101].”
BackgroundStrohmeyer, R., Ramirez, M., Cole, G. J., Mueller, K., & Rogers, J. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00272-2 · Cited by 91
Asgari, E., Farrar, C. A., Lynch, N. J., Ali, Y. M., Roscher, S., Stover, C. M., Zhou, W., Schwaeble, W., & Sacks, S. H. (2014) · The FASEB Journal · doi:10.1096/fj.13-246306 · Cited by 89
“Deposited C3d in the corticomedullary junction was quantified using LUCIA image-analysis software (Jencons-PLS, Leighton Buzzard, UK).”
MethodInfluentialEikelenboom, P., Veerhuis, R., van Exel, E., J.M. Hoozemans, J., J.M. Rozemuller, A., & A. van Gool, W. (2011) · Current Alzheimer Research · doi:10.2174/156720511795256080 · Cited by 88
“Mice double transgenic for hAPP and sCrry (an inhibitor of C3 activation) have 2 to 3 times more A than the hAPP littermates [40].”
BackgroundLinnartz, B., Wang, Y., & Neumann, H. (2010) · International Journal of Alzheimer's Disease · doi:10.4061/2010/587463 · Cited by 87
Ager, R. R., Fonseca, M. I., Chu, S., Sanderson, S. D., Taylor, S. M., Woodruff, T. M., & Tenner, A. J. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06595.x · Cited by 86
“…may facilitate removal of aggregated Ab, as inhibition of C3 cleavage through the over-expression of the complement receptor-related protein y or complete C3 genetic deletion in AD mouse models resulted in a substantial increases in Ab deposition (Wyss-Coray et al. 2002; Maier et al. 2008).”
BackgroundThe interplay between inflammation and neurodegeneration in CNS disease
Esiri, M. M. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.013 · Cited by 91
“Complement seems to play a protective role against β amyloid accumulation in a transgenic mouse model of AD since over-expression of a soluble complement inhibitor, Crry, led to an increased burden of β amyloid and inflammation (Wyss-Coray et al., 2002).”
BackgroundLuchena, C., Zuazo-Ibarra, J., Alberdi, E., Matute, C., & Capetillo-Zarate, E. (2018) · Mediators of Inflammation · doi:10.1155/2018/2530414 · Cited by 82
“As a matter of fact, some complement factors like C3 have been reported to decrease the neuropathology in hAPP mice [43].”
InfluentialQi, X.-M., & Ma, J. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0091-7 · Cited by 93
“However brain Aβ deposition increased when the activation of C3 was inhibited by expressing soluble complement receptor- related protein y (sCrry) in human amyloid precursor (hAPP) transgenic mice [88].”
BackgroundThe Potential Role of Cytokines and Growth Factors in the Pathogenesis of Alzheimer’s Disease
Ogunmokun, G., Dewanjee, S., Chakraborty, P., Valupadas, C., Chaudhary, A., Kolli, V., Anand, U., Vallamkondu, J., Goel, P., Paluru, H. P. R., et al. (2021) · Cells · doi:10.3390/cells10102790 · Cited by 85
Gaikwad, S. M., Larionov, S., Wang, Y., Dannenberg, H., Matozaki, T., Monsonego, A., Thal, D. R., & Neumann, H. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.090147 · Cited by 88
Kam, J. H., Lenassi, E., Malik, T. H., Pickering, M. C., & Jeffery, G. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.04.008 · Cited by 87
Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants
Mayeux, R., & Schupf, N. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.004 · Cited by 79
C1, MBL–MASPs and C1-inhibitor: novel approaches for targeting complement-mediated inflammation
Beinrohr, L., Dobó, J., Závodszky, P., & Gál, P. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.09.009 · Cited by 92
The possible role of complement activation in Alzheimer disease
McGeer, P. L., & McGeer, E. G. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02422-x · Cited by 94
The Complement System in the Central Nervous System: From Neurodevelopment to Neurodegeneration
Chen, Y., Chu, J. M. T., Chang, R. C., & Wong, G. T. C. (2022) · Biomolecules · doi:10.3390/biom12020337 · Cited by 84
“Similarly, overexpression of an endogenous anti-C3 inhibitor protein Crry promotes Aβ plaque formation [73].”
BackgroundAssociation of Peripheral Blood Cell Profile With Alzheimer's Disease: A Meta-Analysis
Huang, L., Zhang, C., Wang, Y., & Wang, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.888946 · Cited by 94
“However, with prolonged inflammation, microglial cells lose their ability to clear the plaque (Wyss-Coray et al., 2002; Simard et al., 2006; Sayed et al., 2020).”
BackgroundImplication of Complement System and its Regulators in Alzheimers Disease
Kolev, M., Ruseva, M., Harris, C., Morgan, B., & Donev, R. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602805 · Cited by 77
“More recently, a protective role of complement in AD was demonstrated in human APP transgenic mice; when complement was blocked by expression of soluble Crry (a rodent CReg with inhibitory activities similar to human CD46 and CD55) [63], mice expressing soluble Crry had a 2-3-fold increase in A accumulation and neuron…”
BackgroundInfluentialSorting Nexin 27 Regulates Aβ Production through Modulating γ-Secretase Activity
Wang, X., Huang, T., Zhao, Y., Zheng, Q., Thompson, R. C., Bu, G., Zhang, Y.-W., Hong, W., & Xu, H. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.09.037 · Cited by 77
Signaling pathways regulating neuron–glia interaction and their implications in Alzheimer's disease
Lian, H., & Zheng, H. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13424 · Cited by 77
“late-age neurodegeneration (Wyss-Coray et al. 2002; Maier et al. 2008; Fu et al. 2012), implicating a detrimental effect of C3 inactivation.”
BackgroundJeon, M.-T., Kim, K.-S., Kim, E. S., Lee, S., Kim, J., Hoe, H.-S., & Kim, D.-G. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101333 · Cited by 76
Remembering your A, B, C's: Alzheimer's disease and ABCA1
Lewandowski, C. T., Laham, M. S., & Thatcher, G. R. J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.011 · Cited by 76
Fas Ligand-Mediated Apoptosis in Degenerative Disorders of the Brain
Ethell, D. W., & Buhler, L. A. (2003) · Journal of Clinical Immunology · doi:10.1023/a:1025317516396 · Cited by 81
“Inhibition of complement by overexpression of complement receptor related protein y (Crry) caused a two- to threefold increase in A β deposition in a hAPP mouse model for AD (73).”
BackgroundVasilevko, V., Passos, G. F., Quiring, D., Head, E., Kim, R. C., Fisher, M., & Cribbs, D. H. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05786.x · Cited by 74
Brennan, F. H., Lee, J. D., Ruitenberg, M. J., & Woodruff, T. M. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.015 · Cited by 76
Snow, A. D., Castillo, G. M., Nguyen, B. P., Choi, P. Y., Cummings, J. A., Cam, J. A., Hu, Q., Lake, T. P., Pan, W., Kastin, A. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38645-0 · Cited by 82
Self-citationInnate Immunity in Alzheimer’s Disease: A Complex Affair
Guillot-Sestier, M.-V., & Town, T. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311312050008 · Cited by 72
The Importance of Complement-Mediated Immune Signaling in Alzheimer’s Disease Pathogenesis
Batista, A. F., Khan, K. A., Papavergi, M.-T., & Lemere, C. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020817 · Cited by 65
“C3 and CR3 also contribute to A β clearance mediated by microglia, thereby supporting the beneficial functions of microglia during AD pathogenesis [96,112,124,125].”
BackgroundCellular and Molecular Mediators of Neuroinflammation in Alzheimer Disease
Yang, S.-H. (2019) · International Neurourology Journal · doi:10.5213/inj.1938184.092 · Cited by 68
“In animal models of early AD development, the immune response induces Aβ clearance through the activation of microglia, indicating that the immune response favorably regulates AD-related pathologies [25-27].”
BackgroundPlaque complement activation and cognitive loss in Alzheimer's disease
Loeffler, D. A., Camp, D. M., & Bennett, D. A. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-9 · Cited by 68
“However, conflicting results with regard to this issue have been obtained from animal studies [14,15].”
ResultToropygin, I. Y., Kugaevskaya, E. V., Mirgorodskaya, O. A., Elisseeva, Y. E., Kozmin, Y. P., Popov, I. A., Nikolaev, E. N., Makarov, A. A., & Kozin, S. A. (2008) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.3357 · Cited by 72
Neuronal localization of C1q in preclinical Alzheimer's disease
Fonseca, M. I., Kawas, C. H., Troncoso, J. C., & Tenner, A. J. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.09.004 · Cited by 71
“C1q as well as other complement proteins may then play a dual role, as supported by studies with transgenic models of AD in which both protective and detrimental roles of complement proteins were seen (Pasinetti et al., 1996; Wyss-Coray et al., 2002).”
Background
Metadata
- Authors
- Wyss-Coray, T., Yan, F., Lin, A. H.-T., Lambris, J. D., Alexander, J. J., Quigg, R. J., & Masliah, E.
- Affiliations
- Gladstone Institute of Neurological Disease and Department of Neurology, University of California, San Francisco, CA 94141; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104; Department of Medicine, Section of Nephrology, University of Chicago, Chicago, IL 60637; and Departments of Neurosciences and Pathology, University of California at San Diego, La Jolla, CA 92093
- University of California, San Francisco (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-07-15
- Volume
- 99
- Issue
- 16
- Pages
- 10837-10842
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC125059
- OpenAlex
- W2047658053
- Cited by
- 446
- References
- 47
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 18 · 2023: 10 · 2022: 13 · 2021: 19 · 2020: 24 · 2019: 21 · 2018: 16 · 2017: 11 · 2016: 13 · 2015: 18 · 2014: 20 · 2013: 17 · 2012: 28
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1r01ag015871-01a1, AG5131, n01ai30040-13-0-5, 5r29ag010869-05, AI-30040, AG10869, AG15871)
- National Institute on Aging (P50AG005131, AG-5131, AG10869, AG15871)
- National Institute of Allergy and Infectious Diseases (AI30040, N01 AI030040)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK41873, DK58820, R56DK041873, R01DK041873, U24DK058820)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Keywords
- Alzheimer's disease, complement activation, complement C3, amyloid-beta deposition, amyloid plaques, neurodegeneration, TGF-β1, microglial activation, innate immunity, amyloid precursor protein transgenic mice, neuroinflammation, amyloid clearance
- MeSH terms
- Alzheimer Disease, Animals, Brain, Complement Activation, Complement C3, Disease Models, Animal, Humans, Mice, Inbred C57BL, Mice, Transgenic, Nerve Degeneration, Neurons, Receptors, Complement, Gene Expression, Amyloid beta-Protein Precursor, Receptors, Complement 3b, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.